HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Phase 1

Withdrawn

• Conditions: Acute Lymphoid Leukemia; Myeloproliferative Disorders; Acute Myeloid Leukemia; Myelofibrosis; Multiple Myeloma; Myelodysplastic Syndromes; Chronic Myeloid Leukemia; Malignant Lymphoma
• Interventions: Drug: MDG1021 dose 1; Drug: MDG1021 dose 2; Drug: MDG1021 dose 3; Drug: MDG1021 optimal dose

• Registration Number: NCT04464889
• Lead Sponsor: Medigene AG

Brief Summary

This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A\*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. The aim of the study is to determine the recommended phase II dose of MDG1021.

Detailed Description

This phase I is designed to assess the safety and feasibility of a HLA-A\*02:01 restricted, HA-1H T cell receptor (TCR) transduced patient-derived T cell (MDG1021) immunotherapy, with secondary endpoints including preliminary efficacy, in patients with relapsed or persistent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. In the dose-escalation part of the study, at least 9 patients will be treated with MDG1021 at 3 different doses to assess the safety and the maximum tolerated dose using a standard 3+3 cohort design. Thereafter, the selected optimal MDG1021 dose will be assessed for safety and preliminary efficacy in 20 additional patients during the dose-expansion part of the study. Manufacturing feasibility will be determined. MDG1021 will be administered by single intravenous infusion.

HA-1H is exclusively expressed on cells of the hematopoietic system. If the patient's blood-cells, and thus lymphoma or leukemic cells, carry the immunogenic version of the HA-1H antigen on their surface and the donor stem cells do not, MDG1021 immunotherapy could eradicate the patient's cancer cells and allow the donor stem cells to repopulate the patient's blood forming system.

Study Timeline

• Study First Submitted: 2020-07-01
• Study Start: 2020-07-02
• Study First Submitted QC: 2020-07-06
• Study First Posted: 2020-07-09
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-30
• Last Update Posted: 2021-10-08
• Primary Completion: 2023-07
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Relapsed or persistent disease is defined according to disease specific guidelines (AML, CML, MM, ALL, MDS, MPN, MF and malignant B- or T-cell lymphoma) and includes MRD positivity.

2. Patients positive for HLA-A*02:01 according to genotyping results

3. Patients positive for HA-1H

4. Patients who received the allo-HSCT at least 100 days preceding the leukapheresis

5. Patients (i.e. recipient) transplanted with a sibling or unrelated HSCT donor

   1. donor being HLA-A*02:01 positive and HA-1H negative, or
   2. a donor with a single mismatch at HLA-A*02:01, being HA-1H positive or negative

6. Patients from whom at least 10x10^6 donor CD8+ T cells can be harvested by leukapheresis

7. Age ≥ 18 years, of either sex

8. ECOG performance status 0-2.

9. Life expectancy of at least 3 months

10. Patients must be able to understand and be willing to give signed informed consent

Read More

Exclusion Criteria

1. Evidence of acute or chronic graft versus host disease (GVHD) ≥ grade II

2. Serologic evidence of acute or chronic hepatitis B virus infection (i.e. positive for HBsAg or IgM anti-HBc). Positive HIV and HCV serology or active bacterial infection

3. Medical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the investigator. Special risks to be considered:

   1. Creatinine > 2.5 times the upper limit of normal (ULN) serum level
   2. Total bilirubin, ALAT, ASAT > 3.0 x ULN serum level
   3. Cardiac left ventricular ejection fraction < 35% at rest
   4. Severe restrictive or obstructive lung disease

4. Clinically significant and ongoing immune suppression including, but not limited to immunosuppressive agents (e.g. cyclosporine or corticosteroids (at an equivalent dose of ≥ 10 mg prednisone per day)). Inhaled steroid and physiological replacement for adrenal insufficiency is allowed

5. Patients with a history of primary immunodeficiency

6. Patients with a currently active second malignancy other than nonmelanoma skin cancers or subjects with history of prior malignancy and previously treated with a curative intent therapy less than 1 year ago

7. Patients both with urinary outflow obstructions and on dialysis or patients for whom cyclophosphamide is contraindicated for other reasons

8. Known or suspected hypersensitivity or intolerance to IMP, cyclophosphamide, fludarabine and/or tocilizumab or to any of the excipients

9. Participation in any clinical study < 60 days prior to first IMP administration in case of antibodies and < 14 days for all other IMPs

10. Vulnerable patients and/or patients unwilling or unable to comply with procedures required in this clinical study protocol

11. Pregnant or lactating women

12. Women of child-bearing potential not using highly effective method(s) of birth control (i.e., with low failure rate < 1% per year) throughout the study and/or unwilling to be tested for pregnancy. A negative serum β-hCG test is required at baseline

13. Fertile men not agreeing to use effective contraceptive methods during the clinical study

    Exclusion criteria at time of IMP administration:

14. Uncontrolled central nervous system (CNS) disease

15. Uncontrolled, life threatening infections or uncontrolled disseminated intravascular coagulation; however, if these problems resolve, the start of treatment can be initiated on a delayed schedule

16. Evidence of acute or chronic graft versus host disease (GVHD) ≥ grade II

17. Unable to generate HA-1H TCR transduced T cells for transfusion (out of specification). However, if a lower than planned number of cells is available, the patient will have the option to receive the OOS HA-1H TCR transduced T cells product (cell dose must be at least the lowest dose level of D1 and will be analyzed in the safety and full analysis set populations.

18. If not enough starting material is collected during leukapheresis, the patient will be excluded from study participation and receive best available standard therapy.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MDG1021	MDG1021 dose 1	Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
MDG1021	MDG1021 dose 2	Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
MDG1021	MDG1021 dose 3	Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
MDG1021	MDG1021 optimal dose	Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.

Primary Outcome Measures

Name	Time	Method
Safety and tolerability of HA-1H TCR transduced T cells: incidence and severity of adverse events	up to 28 days after T cell infusion	To assess the incidence and severity of adverse events during the dose escalation part of the study according to the NCI CTCAE v5.0
Maximum tolerated dose (MTD) of HA-1H TCR transduced T cells	up to 28 days after T cell infusion	To asses the maximum tolerated dose (MTD) of MDG1021 as determined by dose-limiting toxicities (DLTs)
Recommended phase 2 dose (RP2D) of HA-1H TCR transduced T cells	up to 28 days after T cell infusion	To asses the recommended phase II dose (RP2D) of MDG1021
Safety and tolerability of HA-1H TCR transduced T cells at recommended phase II dose: incidence and severity of adverse events	up to 28 days after T cell infusion	To assess the incidence and severity of adverse events of MDG1021 at the RP2D during the expansion part of the study according to the NCI CTCAE v5.0

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability (both parts of the study): incidence and severity of adverse events	Up to 12 months after T cell infusion	To assess the incidence and severity of AEs ≥ grade 3 (NCI CTCAE v5.0)
Overall response rate	Up to 12 months after T cell infusion	To assess the overall response rate defined as the proportion of patients with a best overall response of complete response (CR), partial response (PR), and/or their disease specific subcategories
Overall survival	Up to 12 months afterT cell infusion	To assess the overall survival (OS) defined as the time from the date of signing the informed consent until the documented date of death.
Progression free survival	Up to 12 months afterT cell infusion	To assess the progression-free survival (PFS) defined as the time from the date of signing the date of signed informed consent until progressive disease/relapse or death, whichever occurs first.
Duration of response	Up to 12 months afterT cell infusion	To assess the duration of response (DoR) defined as time from the date of the first documented response to the first documented progression of disease or death due to underlying cancer.
Quality of life (EQ-5D-5L)	Up to 12 months afterT cell infusion	The quality of life will be assessed by using the EQ-5D-5L questionnaire, consisting of 5 questions. Higher scores correspond to higher quality of life.
Quality of life (VAS)	Up to 12 months afterT cell infusion	The quality of life will be assessed by a visual analog scale (EuroQoL), having a range of 0 ot 100, with higher scores corresponding to better quality of life.

Trial Locations

Locations (1)

Leiden University Medical Centre; 🇳🇱 Leiden, Zuid Holland, Netherlands